IPRATROPIUM + SALBUTAMOL INHALER (COMBIVENT)

**Class:** Anticholinergic Agent; Beta2 Agonist

**Indications:**
Treatment of COPD in those patients who are currently on a regular bronchodilator who continue to have bronchospasms and require a second bronchodilator

**Available dosage form in the hospital:**
- IPRATROPIUM 20MCG+ SALBUTAMOL 120MCG INHALER (COMBIVENT)
- IPRATROPIUM 500MCG+ SALBUTAMOL 3.01MG (COMBIVENT) UDV

**Dosage Forms:**
Combivent®: Ipratropium bromide 18 mcg and albuterol (base) 90 mcg per inhalation (14.7 g) [contains chlorofluorocarbon, soya lecithin; 200 metered actuations]

Solution, for nebulization: Ipratropium bromide 0.5 mg and albuterol (base) 2.5 mg per 3 mL (30s, 60s).

**Dosage:**

-COPD: Inhalation:

  - **Aerosol for inhalation:**
    - Combivent®: Two inhalations 4 times daily (maximum: 12 inhalations/24 hours)
    - Combivent® Respimat®: One inhalation 4 times daily (maximum: 6 inhalations/24 hours)

  - **Solution for nebulization:**
    Initial: 3 mL every 6 hours (maximum: 3 mL every 4 hours).

**Geriatric**
Refer to adult dosing.

**Renal Impairment:**
No dosage adjustment provided in manufacturer’s labeling (has not been studied); use with caution.

**Hepatic Impairment:**
No dosage adjustment provided in manufacturer’s labeling (has not been studied); use with caution.

**Common side effect:**

>10%: Respiratory: Bronchitis (2% to 12%), upper respiratory tract infection (3% to 11%)

**Pregnancy Risk Factor:** C